J&J de­clares a his­toric suc­cess as In­vokana comes through in PhI­II chron­ic kid­ney dis­ease tri­al

J&J has scored pos­i­tive da­ta from its Phase III chron­ic kid­ney dis­ease study of the SGLT2 di­a­betes drug In­vokana, pos­si­bly open­ing the door to a come­back af­ter watch­ing sales rev­enue dwin­dle in the face of a safe­ty alert.

Re­searchers said af­ter the mar­ket close $JNJ to­day that they had the snap­shot of promis­ing re­sults they need­ed to call CRE­DENCE a suc­cess and end it ear­ly, “as the tri­al had achieved pre-spec­i­fied cri­te­ria for the pri­ma­ry com­pos­ite end­point of end-stage kid­ney dis­ease (time to dial­y­sis or kid­ney trans­plan­ta­tion), dou­bling of serum cre­a­ti­nine, and re­nal or car­dio­vas­cu­lar (CV) death, when used in ad­di­tion to stan­dard of care.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER